Skip to main content

Research Repository

Advanced Search

In vitro and in vivo evaluation of a sustained-release once-a-day formulation of the novel antihypertensive drug MT-1207

Vrettos, Napoleon-Nikolaos; Wang, Peng; Zhou, Yan; Roberts, Clive J.; Xu, Jinyi; Yao, Hong; Zhu, Zheying

In vitro and in vivo evaluation of a sustained-release once-a-day formulation of the novel antihypertensive drug MT-1207 Thumbnail


Authors

Napoleon-Nikolaos Vrettos

Peng Wang

Yan Zhou

Jinyi Xu

Hong Yao

ZHEYING ZHU Zheying.Zhu@nottingham.ac.uk
Associate Professor in International Pharmacy and Traditional Medicines



Abstract

Hypertension is one of the most common chronic cardiovascular disorders. Sustained-release formulations are developed to maintain drug therapeutic levels throughout the treatment of hypertension, to promote patient compliance and improve patient outcomes. We have developed and tested in in vivo trials a once-a-day tablet formulation for the novel antihypertensive drug MT-1207. The tablets based upon a hydrophilic polymer matrix underwent post-compression parameter and physicochemical characterisations, along with in vitro drug release testing. The most promising formulation containing 31% w/w HPMC K15M gave a 24-hour release of MT-1207 with an almost constant release rate up to 20 hours. Follow in in vivo studies were carried out in Beagle dogs for the optimised sustained-release tablets in comparison to immediate-release tablets. The results showed that a sustained release of MT-1207 from the new formulation was achieved with a drug t1/2 2–2.5 times longer than the immediate-release tablets. Moreover, the AUC0-24h values of both sustained- and immediate-release tablets were identical at the same dose of 30 mg, indicating that the same amount of drug was absorbed in each case. For treatments based upon MT-1207, this development is significant for future commercial exploitation via scale-up and further trials, and for improved patient outcomes.

Citation

Vrettos, N., Wang, P., Zhou, Y., Roberts, C. J., Xu, J., Yao, H., & Zhu, Z. (2021). In vitro and in vivo evaluation of a sustained-release once-a-day formulation of the novel antihypertensive drug MT-1207. Pharmaceutical Development and Technology, 26(3), 349-361. https://doi.org/10.1080/10837450.2021.1872087

Journal Article Type Article
Acceptance Date Jan 2, 2021
Online Publication Date Jan 13, 2021
Publication Date Jan 13, 2021
Deposit Date Jan 17, 2021
Publicly Available Date Jan 14, 2022
Journal Pharmaceutical Development and Technology
Print ISSN 1083-7450
Electronic ISSN 1097-9867
Publisher Taylor & Francis Open
Peer Reviewed Peer Reviewed
Volume 26
Issue 3
Pages 349-361
DOI https://doi.org/10.1080/10837450.2021.1872087
Keywords Pharmaceutical Science; General Medicine
Public URL https://nottingham-repository.worktribe.com/output/5234666
Publisher URL https://www.tandfonline.com/doi/full/10.1080/10837450.2021.1872087
Additional Information This is an Accepted Manuscript of an article published by Taylor & Francis in Pharmaceutical Development and Technology on 13/1/2021, available online: http://www.tandfonline.com/10.1080/10837450.2021.1872087

Files




You might also like



Downloadable Citations